Is Maravai Lifesciences Holdings, Inc. overvalued or undervalued?

As of 22 February 2024, the valuation grade for Maravai Lifesciences Holdings, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.02 and an EV to Sales ratio of 2.56, which suggest that investors are paying a premium for its assets and sales relative to its peers. Additionally, the EV to EBITDA ratio stands at -23.39, highlighting significant operational challenges.
In comparison to its peer Zentalis Pharmaceuticals, which has a more favorable EV to EBITDA of 1.0769, Maravai's financial ratios reflect a concerning position within the Pharmaceuticals & Biotechnology industry. The company's recent stock performance has been notably poor, with a year-to-date return of -47.16% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that Maravai is struggling significantly in the current market environment.